PhRMA Appoints Amgen Chairman and CEO as New PhRMA Chairman
The Pharmaceutical Research and Manufacturers of America (PhRMA), an industry trade group of innovator, research-based pharmaceutical companies, has appointed three new officers. Robert A. Bradway, chairman and chief executive officer (CEO), Amgen, has been named chairman of the PhRMA board of directors. Olivier Brandicourt, CEO, Sanofi was named chairman-elect, and James Robinson, president, Astellas Americas, assumed the role of board treasurer.
Bradway formerly held the position of board treasurer and succeeds Joaquin Duato, executive vice president and worldwide chairman, pharmaceuticals, Johnson & Johnson as PhRMA board chairman. Bradway has been Amgen’s chairman since 2013 and CEO since 2012. He joined the company in 2006 and served as the company’s president and chief operating officer prior to the role of CEO. Bradway is a member of the board of directors of The Boeing Company. He serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at the university. Bradway is also chairman of the CEO Roundtable on Cancer and a member of the American Heart Association’s CEO Roundtable.
Chairman-elect Brandicourt has served as CEO, Sanofi, since April 2015. Brandicourt joined Sanofi from Bayer Healthcare AG, where he served as CEO from 2013 until 2015. Prior to joining Bayer Healthcare, Brandicourt worked at Pfizer for 13 years, where he served as a member of the executive leadership team and as president and general manager of the Emerging Markets and Established Products Business Units. He is an honorary member of the Royal College of Physicians in London and a board member of the Children’s Aid Society in New York.
Newly named treasurer Robinson has been president, Astellas Americas, since April 2016. Previously, he led the company’s pharmaceutical commercial organization in the US. Robinson joined the company in 2005 as vice president of health systems. Prior to joining Astellas, he served as vice president of hepatitis sales and managed care at the former Schering-Plough Corporation, which was acquired by Merck & Company in 2009. He is a founding member and serves on the board of directors of Matter, a group focused on creating products and services that advance the healthcare industry. He also serves on the board of directors of the Chicago Botanic Garden and the board of trustees of the Museum of Science and Industry.
